多学科团队干预对远程转移性结直肠癌的长期生存的影响:单中心倾向性得分分析
Tetsuo Sugishita1,2, Yukihide Kanemitsu1, Jun Imaizumi1
1Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
概括
在远程转移性结直肠癌 (DMCRC) 患者的多学科团队 (MDT) 干预显著改善了整体存活率. 这种方法增加了治疗意图的手术,这表明DMCRC患者的长期预后更好.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 癌症治疗方法 癌症治疗方法
背景情况:
- 建议多学科团队 (MDT) 干预远程转移性结直肠癌 (DMCRC).
- MDT干预对DMCRC长期预后的影响尚不清楚.
研究的目的:
- 研究MDT干预对改善DMCRC患者长期预后的影响.
- 确定MDT干预是否与更好的整体存活率 (OS) 有关.
主要方法:
- 在2013-2017年期间治疗的404名DMCRC患者的回顾性分析.
- 分类为MDT和非MDT组.
- 进行了多变量分析 (Cox比例危险) 和三个倾向性评分分析 (回归调整,分层,匹配).
主要成果:
- MDT干预显着与改善的OS相关 (HR 0.687,p=0.011).
- 倾向性得分匹配显示,在MDT组中,治疗意图手术的比率更高.
- 在MDT组中,中位数的生存期往往更长 (32.8个月与24.1个月,p=0.088).
- 回归调整和分层分析证实了MDT干预与OS改善的关联.
结论:
- 在DMCRC中,MDT干预与改善整体存活率有关.
- 在MDT病例中,治疗意图手术的更高率表明,长期生存结果可能会得到改善.
更多相关视频
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.6K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.9K
相关概念视频
Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
